Servier buys into MacroGenics' Phase I anticancer MAb
This article was originally published in Scrip
Servier is to pay an initial $20 million to Rockville, Maryland-based privately held biotech firm MacroGenics to access the latter's MGA271, an Fc-optimised therapeutic monoclonal antibody that targets the immune regulator B7-H3 and is in Phase I trials to treat solid tumours.
You may also be interested in...
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.